KainosMed Completes Dosing in US Phase 1b Clinical Trial for Parkinson's Disease Treatment

[Asia Economy Reporter Hyunseok Yoo] Kainosmed announced on the 5th that the dosing of clinical subjects in the US Phase 1b clinical trial of the Parkinson's disease treatment (KM-819) has been completed as scheduled.

Kainosmed introduced a new formulation with significantly improved drug absorption (bioavailability) compared to the formulation used in Phase 1 and is conducting the Phase 1b trial through its subsidiary Fascinate.

This Phase 1b trial was conducted over one month with 8 healthy adult males, administering the existing formulation first and then the new formulation to the same subjects to measure the absorption of KM-819.

With the completion of dosing in the Phase 1b trial, Kainosmed plans to prepare the clinical report and submit the Phase 2 clinical trial plan (IND) to the US Food and Drug Administration (FDA) by the first half of this year.

Meanwhile, Kainosmed disclosed on the same day that it sold 23,255 shares of NextBio it held for 1,860.4 million KRW, generating a capital gain of 1,360.4 million KRW.

This content was produced with the assistance of AI translation services.